CHEYANNE WILLIAMSON: Open Payments
NPI 1487176236 · MANHATTAN, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 53 payments from 16 companies in 2025. Trend: 2023 $260 · 2024 $265 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $179 |
| ABBVIE INC. | 13 | $175 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
| Abbott Laboratories | 2 | $76 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Lilly USA, LLC | 3 | $54 |
| GlaxoSmithKline, LLC. | 3 | $45 |
| CSL Behring | 1 | $35 |
| Novo Nordisk Inc | 2 | $34 |
Products named: VRAYLAR, CAPLYTA, FREESTYLE LIBRE 3, PREVNAR 20, REXULTI, UBRELVY, ELIQUIS, AIRSUPRA.
Industry payments across KS — which companies pay providers there.
